Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study
Author(s)
Dina Abushanab, MSc1, Sarah Awwad, BPharm2, Mouda Hamdan, BPharm2, Anas Hamad, MSc, PhD3, Manal Zidan, PharmD4, Daoud Al-Badriyeh, PhD5.
1Ms, Monash University, Melbourne, Australia, 2Qatar University, Doha, Qatar, 3Hamad Medical Corporation, London, United Kingdom, 4Primary healthcare corporation, Doha, Qatar, 5College of Pharmacy, Qatar University, Doha, Qatar.
1Ms, Monash University, Melbourne, Australia, 2Qatar University, Doha, Qatar, 3Hamad Medical Corporation, London, United Kingdom, 4Primary healthcare corporation, Doha, Qatar, 5College of Pharmacy, Qatar University, Doha, Qatar.
OBJECTIVES: This study evaluated the cost-effectiveness of four evidence-based interventions to reduce cardiovascular disease (CVD) risk: lifestyle modification, systolic blood pressure control, smoking cessation, and cholesterol management among individuals with type 2 diabetes at risk of CVD, using a locally calibrated dynamic Markov model.
METHODS: A 10-year cost-effectiveness analysis (2024-2033) was conducted from healthcare and societal perspectives, simulating 48,009 individuals living in Qatar with type 2 diabetes aged 40-79. The four interventions were i) lifestyle modification, ii) systolic blood pressure (SBP) reduction, iii) smoking cessation, and iv) LDL-C reduction. Outcomes were assessed using quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), with USD 150,000/QALY as the willingness-to-pay threshold. Sensitivity analyses were performed to confirm the findings.
RESULTS: The cost-effectiveness analysis revealed variations in the ICERs among the four interventions. The results highlight the cost-effectiveness of all four interventions. Diabetes prevention was highly cost-effective, with an ICER of 44,807 QAR (95% confidence interval: 42,302.76-47,311.24), while LDL-C control demonstrated high value for money, at 87,891 QAR (95% confidence interval: 84,556.06-91,225.94). Smoking cessation emerged as the most effective option, saving costs and improving outcomes (dominant strategy). In contrast, systolic blood pressure control showed an ICER 240,997 QAR (95% CI: 236,958.47- 245,035.53).
CONCLUSIONS: This study demonstrates that CVD risk modifying interventions are cost-effective in type 2 diabetes population in Qatar. These results support the integration of these strategies to achieve the best outcome for society. Future research is needed to explore real-world implementation of the interventions.
METHODS: A 10-year cost-effectiveness analysis (2024-2033) was conducted from healthcare and societal perspectives, simulating 48,009 individuals living in Qatar with type 2 diabetes aged 40-79. The four interventions were i) lifestyle modification, ii) systolic blood pressure (SBP) reduction, iii) smoking cessation, and iv) LDL-C reduction. Outcomes were assessed using quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs), with USD 150,000/QALY as the willingness-to-pay threshold. Sensitivity analyses were performed to confirm the findings.
RESULTS: The cost-effectiveness analysis revealed variations in the ICERs among the four interventions. The results highlight the cost-effectiveness of all four interventions. Diabetes prevention was highly cost-effective, with an ICER of 44,807 QAR (95% confidence interval: 42,302.76-47,311.24), while LDL-C control demonstrated high value for money, at 87,891 QAR (95% confidence interval: 84,556.06-91,225.94). Smoking cessation emerged as the most effective option, saving costs and improving outcomes (dominant strategy). In contrast, systolic blood pressure control showed an ICER 240,997 QAR (95% CI: 236,958.47- 245,035.53).
CONCLUSIONS: This study demonstrates that CVD risk modifying interventions are cost-effective in type 2 diabetes population in Qatar. These results support the integration of these strategies to achieve the best outcome for society. Future research is needed to explore real-world implementation of the interventions.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE121
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity)